# EDGAR Filing Document

**Accession Number:** 0001979005
**File Stem:** 0001493152-26-031065
**Filing Date:** 2026-6
**Character Count:** 6396
**Document Hash:** 26940678776ea186803f7fadfd7ef467
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-031065.hdr.sgml**: 20260629

**ACCESSION NUMBER**: 0001493152-26-031065

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260624

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260629

**DATE AS OF CHANGE**: 20260629

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aimei Health Technology Co., Ltd.
- **CENTRAL INDEX KEY:** 0001979005
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41880
- **FILM NUMBER:** 261135721

**BUSINESS ADDRESS:**
- **STREET 1:** 10 EAST 53RD STREET
- **STREET 2:** SUITE 3001
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 34 678 035200

**MAIL ADDRESS:**
- **STREET 1:** 10 EAST 53RD STREET
- **STREET 2:** SUITE 3001
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

?xml version='1.0' encoding='ASCII'?

**United States**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**June 24, 2026**

Date of Report (Date of earliest event reported)

**<u>AIMEI HEALTH TECHNOLOGY CO., LTD</u>**

(Exact Name of Registrant as Specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Cayman Islands** | **001-41880** | **N/A** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **10 East 53rd Street, Suite 3001**<br> **New York, NY** | **10022** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**86-13758131392**

Registrant's telephone number, including area code

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each Class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Ordinary Shares, par value $0.0001 per share | AFJK | The Nasdaq Stock Market LLC |
| Rights, exchangeable into one-fifth of one Ordinary Share | AFJKR | The Nasdaq Stock Market LLC |
| Units, each consisting of one Ordinary Share and one Right | AFJKU | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers.**

On June 24, 2026, Ms. Julianne Huh, a director of Aimei Health Technology Co., Ltd (the "***Company***"), submitted a letter of resignation indicating her intention to resign as the Company's director, effective June 24, 2026, which has been accepted by the board of directors of the Company (the "***Board***"). Ms. Huh has advised the Company that her resignation was due to personal reasons and not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. Ms. Huh has acknowledged that she has been paid all amounts due to her and she is not entitled to any payments or benefits of any kind from the Company, and she has irrevocably and unconditionally released the Company of and from all claims, demands, actions, and causes of action.

On June 29, 2026, the nominating and corporate governance committee of the Board recommended, and the Board approved and appointed Mr. Daniel Veikko Polvi to serve as a director of the Company. Mr. Polvi received his MBA degree in Business Administration from BI Norwegian Business School in June 2018. Since May 2019, Mr. Polvi has served as the managing director of Shearwater Limited, a management consulting firm providing business management consulting services to international corporations, where he is responsible for overseeing client engagements and delivering business and management consulting services to international corporate clients. The Board believes that Mr. Polvi is well qualified to serve as a director of the Company due to his extensive experience in business management, corporate advisory, and strategic consulting for international corporations.

There are no family relationships between Mr. Polvi and any director or executive officer of the Company. To the best knowledge of the Company, neither Mr. Polvi nor any of his immediate family members is a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

**Item 9.01. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 29, 2026

---

| | |
|:---|:---|
| **Aimei Health Technology Co., Ltd** | **Aimei Health Technology Co., Ltd** |
| By: | */s/ Junheng Xie* |
| Name: | Junheng Xie |
| Title: | Chief Executive Officer and Director |
|  | (Principal Executive Officer) |

---